ClinicalTrials.gg
CompletedNCT05851066Updated Sep 12, 2025

A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers

A Phase 1 interventional study of VSA003 and 0.9% NaCl in Dyslipidemias, Familial Hypercholesterolemia and Hypertriglyceridemia, sponsored by Visirna Therapeutics HK Limited. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Visirna Therapeutics HK Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Dyslipidemias with a site in China — 21 open to participants now, 31 under way, 10 of them phase 3. Dyslipidemias · China.

Enrollment
52nd of 56
36 · median 213
Started
2023
with 4 others
Phase 1
6 of 73
1 open now
Registered
47th of 73
by date

Among the 73 studies in Dyslipidemias with a site in China, this one is the 52nd largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2023, is one of 6 in phase 1, and was the 47th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

21 of the 73 studies in Dyslipidemias with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Dyslipidemias with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double blinded, phase 1 study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of VSA003 in healthy adult volunteerst

03

Conditions studied

  • Dyslipidemias
  • Familial Hypercholesterolemia
  • Hypertriglyceridemia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use
  • 18.0\~28.0 kg/m2
  • Willing to provide written and to comply with study requirements
  • On a stable diet for at least 4 weeks with no plans to significantly alter diet or weight over course of study
  • TG> 100 mg/dL
  • LDL-C> 70 mg/dL

Exclusion criteria

Exclusion Criteria:

  • health concerns
  • Regular use of alcohol within one month prior to screening
  • Recent (within 3 months) use of illicit drugs
  • Female with pregnancy or breastfeeding
  • >450 ms in
  • Donation or loss of whole blood more than 400 ml prior to administration of the study treatment

Note: additional inclusion/exclusion criteria may apply, per protocol

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    VSA003

    single dose of VSA003 by subcutaneous (sc) injections: 50 mg, 100 mg, 200 mg

    Drug: VSA003

  • Placebo comparator
    placebo

    sterile normal saline (0.9% NaCl) calculated volume to match active treatment

    Drug: 0.9% NaCl

Interventions

  • DrugVSA003

    sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg

  • Drug0.9% NaCl

    placebo

06

What researchers measure

Primary outcomes

  1. Frequency and severity of adverse event (AE) and serious adverse event (SAE)

    safety and tolerability

    Time frame: Up to 85±3 days post-dose

Secondary outcomes

  1. Maximum observed concentration (Cmax) of VSA003

    pharmacokinetics (PK)

    Time frame: Up to 48 hours post dose

  2. Time of occurrence of Cmax (tmax) of VSA003

    PK

    Time frame: Up to 48 hours post dose

  3. Apparent terminal phase half-life (t1/2) of VSA003

    PK

    Time frame: Up to 48 hours post dose

  4. Area under the concentration-time curve from time zero (pre-dose) to the last quantifiable concentration (AUC0-t) of VSA003

    PK

    Time frame: Up to 48 hours post dose

  5. Apparent clearance (CL/F) of VSA003

    PK

    Time frame: Up to 48 hours post dose

  6. Apparent terminal phase volume of distribution (Vz/F) of VSA003

    PK

    Time frame: Up to 48 hours post dose

  7. Change of fasting serum ANGPTL3 from pre-dose baseline

    PD

    Time frame: Up to 85±3 days post-dose

  8. Anti-drug Antibodies (ADA) to VSA003

    immunogenecity

    Time frame: Up to 85±3 days post-dose

Other outcomes

  1. Change of low density lipoprotein cholesterol (LDL-C) from pre-dose baseline

    Lipid profile

    Time frame: Up to 85±3 days post-dose

  2. Change of total cholesterol (TC) from pre-dose baseline

    Lipid profile

    Time frame: Up to 85±3 days post-dose

  3. Change of triglyceride (TG) from pre-dose baseline

    Lipid profile

    Time frame: Up to 85±3 days post-dose

  4. Change of high density lipoprotein cholesterol (HDL-C) from pre-dose baseline

    Lipid profile

    Time frame: Up to 85±3 days post-dose

  5. Change of fasting glucose from pre-dose baseline

    glucose metabolism

    Time frame: Up to 85±3 days post-dose

  6. Change of HbA1c from pre-dose baseline

    glucose metabolism

    Time frame: Up to 85±3 days post-dose

  7. Change of fasting C peptide from pre-dose baseline

    glucose metabolism

    Time frame: Up to 85±3 days post-dose

  8. Change of fasting insulin from pre-dose baseline

    glucose metabolism

    Time frame: Up to 85±3 days post-dose

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in May 2024, 11 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 11 months is above that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
May 9, 2023
StartActual
Jun 1, 2023
Primary completionActual
May 7, 2024
CompletionActual
May 7, 2024
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05851066
Lead sponsor
Visirna Therapeutics HK Limited
Responsible party
Sponsor
First posted
May 9, 2023
Start date
Jun 1, 2023
Primary completion
May 7, 2024
Completion
May 7, 2024
Last update
Sep 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion